The Cost of Finding Problems Late
In pharmaceutical development, the same problem costs vastly different amounts depending on when it surfaces. A solubility issue identified during pre-formulation screening costs a few weeks and a reformulation study. The same issue discovered during a GMP manufacturing campaign costs that, plus the failed batch, plus the regulatory amendment, plus the delay to your clinical timeline.
Early-stage drug development is fundamentally about de-risking. The goal is to surface the problems that could derail your programme when they are still cheap to fix, and to build the evidence base that lets you move into GMP manufacturing with confidence.
The Most Common Formulation Showstoppers
| Risk Category | Common Manifestation | When It Surfaces Without Mitigation | Mitigation Approach |
| Poor aqueous solubility | Drug precipitates in dissolution, low bioavailability | Phase I PK disappointment | BCS classification, solubility screening, ASD or nanosuspension strategy |
| Polymorphic instability | Crystal form converts during processing or storage | Stability failure post-GMP | Polymorph screening, XRPD monitoring, controlled manufacturing conditions |
| Chemical instability | API degrades under heat, light, or humidity | OOS stability data | Stress testing, excipient compatibility, packaging selection |
| Manufacturability issues | Blend flows poorly, tablets cap or laminate | Failed GMP batch | Small-scale feasibility studies, equipment-specific evaluation |
| Bioavailability gap | Animal PK does not translate to human | Phase I PK/PD failure | Human-predictive dissolution, in vitro in vivo correlation modelling |
Building a De-Risking Strategy for Your Molecule
Start with the Physical Chemistry
Before any formulation work begins, a thorough characterisation of the API’s physical chemistry is essential. Solubility across the pH range relevant to the GI tract, log P or log D, pKa, melting point, thermal behaviour, and hygroscopicity all inform which formulation strategies are viable and which are not. ICH Q6A provides the quality test procedures framework for new drug substances that underpins this characterisation work.
Do Not Skip Solid-State Screening
The crystal form you first synthesise is rarely the best one for a stable, manufacturable drug product. Polymorph screening identifies the energetically stable forms and establishes which form you are working with. Salt selection can dramatically improve solubility and chemical stability. Conducting this work early, before a crystalline form becomes locked into your process, avoids expensive changes later.
Stress Testing Before GMP
Accelerated and stress stability studies run at high temperature, humidity, and under photolytic conditions are a standard way to predict the degradation behaviour of a new molecule and its formulated product. Running abbreviated stress studies before committing to a formulation approach is a low-cost insurance policy against stability surprises in GMP storage.
How Ardena Builds De-Risking into Every Programme
Ardena’s development programmes are structured around progressive de-risking. The solid-state research team in Ghent conducts polymorph and salt screening as an integrated part of the formulation strategy, not as a standalone activity. The analytical teams develop methods that are fit for purpose at each stage, rather than designing GMP-validated methods before the formulation is stable.
When pre-formulation data suggests a solubility challenge, the team can draw on a range of enabling technologies, including amorphous solid dispersions by spray drying or hot melt extrusion, nanosuspensions, and lipid-based formulations, depending on the molecule’s properties and the target product profile.
